← Leaderboards
Diana I Jalal
Iowa City Va Medical Center
$3,822,446
Attributed
$5,092,473
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $640.9K · FY2010–25$1M$750K$500K$250K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,092,473 · 3
VA$0 · 1
By mechanism
R01$4,195,533 · 2
K23$896,940 · 1
I01$0 · 1
Top collaborators
- Richard J Smith3 shared
- Joshua M Thurman3 shared
Others in their field
Top investigators on “High Risk”
- Lawrence Corey · Fred Hutchinson Cancer Center$561,333,990
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$424,554,257
- Wafaa M. El-Sadr · Columbia University Health Sciences$337,188,987
- Gary D Acton · University Of California-Davis$320,373,312
- Mitchell J Malone · Texas A&M Research Foundation$320,373,312
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$303,724,352
Research focus
High RiskCardiovascular DiseasesChronic Kidney FailureCardiovascular Disorder RiskClinical TrialsDisease ProgressionAlbuminuriaInflammationPatient PopulationMediatingUniversitiesMeasurementRandomizedBrachial ArteryEndotheliumResearch PersonnelRisk FactorsFuturePlayPlasmaPositioning AttributeCardiovascular Risk FactorComplexPathway Interactions
Grant awards (15)
The Alternative Pathway of Complement: A Potential Contributor to Adverse Outcomes in CKD$640,948
R01 · FY2025 · DK · contact PI
Pharmacist-guided, patient-driven management of high blood pressure in CKD: A Novel Approach$0
I01 · FY2025 · VA · contact PI
The Alternative Pathway of Complement: A Potential Contributor to Adverse Outcomes in CKD$634,659
R01 · FY2024 · DK · contact PI
Pharmacist-guided, patient-driven management of high blood pressure in CKD: A Novel Approach$0
I01 · FY2024 · VA · contact PI
The Alternative Pathway of Complement: A Potential Contributor to Adverse Outcomes in CKD$629,433
R01 · FY2023 · DK · contact PI
Pharmacist-guided, patient-driven management of high blood pressure in CKD: A Novel Approach$0
I01 · FY2022 · VA · contact PI
Curcumin Supplementation for Improving Vascular and Cognitive Function$564,708
R01 · FY2020 · HL · contact PI
Curcumin Supplementation for Improving Vascular and Cognitive Function$564,708
R01 · FY2019 · HL · contact PI
Curcumin Supplementation for Improving Vascular and Cognitive Function$563,488
R01 · FY2018 · HL · contact PI
Curcumin Supplementation for Improving Vascular and Cognitive Function$597,589
R01 · FY2017 · HL · contact PI
Uric Acid as a Mediator of Endothelial Dysfunction in Patients with CKD$179,388
K23 · FY2014 · DK · contact PI
Uric Acid as a Mediator of Endothelial Dysfunction in Patients with CKD$179,388
K23 · FY2013 · DK · contact PI
Uric Acid as a Mediator of Endothelial Dysfunction in Patients with CKD$179,388
K23 · FY2012 · DK · contact PI
Uric Acid as a Mediator of Endothelial Dysfunction in Patients with CKD$179,388
K23 · FY2011 · DK · contact PI
Is Uric Acid a Mediator of Endothelial Dysfunction in Patients with Chronic Kidne$179,388
K23 · FY2010 · DK · contact PI